獸醫再生醫學市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球獸醫再生醫學市場價值為 3.449 億美元，預計到 2034 年將以 12.3% 的複合年成長率成長，達到 11 億美元。推動這一成長的因素包括寵物數量的增加、人們對創新獸醫治療方案的認知不斷提高，以及伴侶動物慢性和退化性疾病的穩定增加。隨著寵物主人繼續優先考慮為他們的動物提供高品質的醫療保健，對幹細胞治療和富血小板血漿療法等再生療法的需求正在成長。獸醫擴大採用這些療法來解決老年寵物和受傷動物的疼痛、發炎和組織修復問題。由於公私機構的大力資金支持，再生醫學也變得越來越容易取得。隨著生物技術的不斷突破和臨床證據的支持，再生方法的應用正在世界各地的獸醫診所中迅速擴展。微創和長期治療方案的轉變正在改變獸醫實踐中治療慢性疼痛、肌肉骨骼損傷和退化性疾病的方式。

光是狗類市場在 2024 年就創造了 2.256 億美元的收入，預計到 2034 年將達到 7.018 億美元，這表明針對韌帶損傷、關節炎和關節退化等常見問題的治療方法的需求強勁。隨著狗狗年齡的成長，它們更容易出現肌肉骨骼併發症，促使寵物主人和獸醫尋求增強活動能力和減輕疼痛的先進解決方案。組織工程、幹細胞療法和富含血小板的血漿等治療方法已被證明對恢復犬類患者功能和改善其生活品質特別有效。這一趨勢正在推動診所將再生醫學融入老年或受傷狗的常規護理中。

按產品類別分類，幹細胞療法在 2024 年佔據了 52.1% 的主導市場。由於已被證明具有促進組織再生、減少發炎和加速恢復的能力，該領域將繼續蓬勃發展。在獸醫臨床試驗不斷增加和治療用途日益廣泛的推動下，自體和異體幹細胞應用正在業界快速發展。這些進步使得幹細胞療法成為動物照護中最有前景和最廣泛接受的治療方式之一，特別是對於狗和馬。

2024 年，美國獸醫再生醫學市場規模達 9,780 萬美元，這得益於先進的醫療基礎設施、高寵物收養率以及​​越來越多的患有關節和肌肉疾病的動物。行業領導者的出現、研發投入的增加以及專業再生服務的廣泛普及進一步加強了該國的市場地位。支持性監管措施和以創新為重點的補助也在推動國內成長方面發揮關鍵作用。

為了佔領更大的市場佔有率，Vetherapy、Animal Cell Therapies、Cell Therapy Sciences、VetStem、Lynch Biologics、Boehringer Ingelheim International、Dechra Pharmaceuticals、Regen Lab、Magellan Stem Cells、Enso Discoveries、Ardent、EquiCord 和 Medrego 等主要參與者正在投入創新和策略性研究。公司正在加強臨床試驗、投資下一代生物製劑並開發可擴展的再生療法。與獸醫診所的合作、教育推廣和全球分銷策略對於滿足日益成長的需求和加強市場地位仍然至關重要。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 慢性病和退化性疾病發生率上升
    • 再生醫學的不斷進步
    • 增加研發投入
    • 寵物擁有量和醫療保健支出不斷成長
  • 產業陷阱與挑戰
    • 治療相關的不良反應
    • 監理合規挑戰
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 各國寵物數量
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按動物類型，2021 - 2034 年

• 主要趨勢
• 狗
• 貓
• 馬匹
• 其他動物類型

第6章：市場估計與預測：依產品類型，2021 - 2034 年

• 主要趨勢
• 幹細胞療法
  • 自體
  • 同種異體
• 生物治療
  • 富血小板血漿（PRP）
  • 生長因子
• 組織工程

第7章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 骨科
• 創傷/傷口護理
• 其他應用

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 獸醫院
• 獸醫診所
• 學術機構和研究機構

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Animal Cell Therapies
• Ardent
• Boehringer Ingelheim International
• Cell Therapy Sciences
• Dechra Pharmaceuticals
• Enso Discoveries
• EquiCord
• Lynch Biologics
• Magellan Stem Cells
• Medrego
• Regen Lab
• Vetherapy
• VetStem

The Global Veterinary Regenerative Medicine Market was valued at USD 344.9 million in 2024 and is estimated to grow at a CAGR of 12.3% to reach USD 1.1 billion by 2034. This growth is being fueled by a rising pet population, a growing awareness of innovative veterinary treatment options, and a steady increase in chronic and degenerative conditions among companion animals. As pet owners continue to prioritize high-quality healthcare for their animals, the demand for regenerative therapies like stem cell treatment and platelet-rich plasma therapy is gaining traction. Veterinarians are increasingly turning to these therapies to address pain, inflammation, and tissue repair in aging pets and animals with injuries. Regenerative medicine is also becoming more accessible thanks to strong financial support from both public and private institutions. With ongoing breakthroughs in biotechnology and supportive clinical evidence, the adoption of regenerative approaches is expanding rapidly across veterinary clinics worldwide. The shift toward minimally invasive and long-lasting treatment options is changing how chronic pain, musculoskeletal injuries, and degenerative disorders are being managed in veterinary practices.

The dog segment alone generated USD 225.6 million in 2024 and is expected to reach USD 701.8 million by 2034, signaling robust demand for therapies that target common issues like ligament injuries, arthritis, and joint degeneration. As dogs age, they're more susceptible to musculoskeletal complications, prompting both pet owners and veterinarians to seek advanced solutions that enhance mobility and reduce pain. Treatments such as tissue engineering, stem cell therapies, and platelet-rich plasma are proving especially effective in restoring function and improving quality of life for canine patients. The trend is pushing clinics to integrate regenerative medicine into routine care for aging or injured dogs.

By product category, stem cell therapy accounted for a dominant 52.1% market share in 2024. This segment continues to thrive due to its proven ability to promote tissue regeneration, minimize inflammation, and accelerate recovery. The industry is witnessing rapid development in both autologous and allogeneic stem cell applications, driven by increasing veterinary clinical trials and broader therapeutic use. These advances are making stem cell therapy one of the most promising and widely accepted treatment modalities in animal care, particularly for dogs and horses.

The U.S. Veterinary Regenerative Medicine Market brought in USD 97.8 million in 2024, backed by cutting-edge healthcare infrastructure, a high rate of pet adoption, and a growing number of animals suffering from joint and muscular disorders. The presence of leading industry players, rising R&D investments, and wider availability of specialized regenerative services have further strengthened the country's market position. Supportive regulatory initiatives and innovation-focused grants are also playing a key role in driving domestic growth.

To capture greater market share, key players such as Vetherapy, Animal Cell Therapies, Cell Therapy Sciences, VetStem, Lynch Biologics, Boehringer Ingelheim International, Dechra Pharmaceuticals, Regen Lab, Magellan Stem Cells, Enso Discoveries, Ardent, EquiCord, and Medrego are doubling down on product innovation and strategic research partnerships. Companies are ramping up clinical trials, investing in next-gen biologics, and developing scalable regenerative therapies. Partnerships with veterinary clinics, educational outreach, and global distribution strategies remain central to meeting growing demand and reinforcing market presence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and degenerative conditions
    • 3.2.1.2 Growing advancement in regenerative medicine
    • 3.2.1.3 Increasing research and development investments
    • 3.2.1.4 Growing pet ownership and healthcare spending
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Treatment-related adverse effects
    • 3.2.2.2 Regulatory compliance challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pet population by country
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell therapy
  • 6.2.1 Autologous
  • 6.2.2 Allogeneic
• 6.3 Biological therapy
  • 6.3.1 Platelet-rich plasma (PRP)
  • 6.3.2 Growth factor
• 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Orthopedics
• 7.3 Trauma/ wound care
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Animal Cell Therapies
• 10.2 Ardent
• 10.3 Boehringer Ingelheim International
• 10.4 Cell Therapy Sciences
• 10.5 Dechra Pharmaceuticals
• 10.6 Enso Discoveries
• 10.7 EquiCord
• 10.8 Lynch Biologics
• 10.9 Magellan Stem Cells
• 10.10 Medrego
• 10.11 Regen Lab
• 10.12 Vetherapy
• 10.13 VetStem